AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

The pharmaceutical company said the investment in the research-and-development center in Beijing will bolster its footprint ...

Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...

AstraZeneca is investing $2.5bn in research and development and manufacturing in Beijing, as the drugmaker tries to move on after a scandal that led to the detention of a top executive in China .

AstraZeneca (AZN) stock in focus as the company invests $2.5B in Beijing for a new R&D center, strengthening its footprint in ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.

The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma ...

Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader AstraZeneca to develop potential ...

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...